Dr Ajoeb Baridi’s Post

Pharmaceutical industry updates 💊 In the pharmaceutical frontier, a week can turn the tides of health innovation—and it just did. As we reflect over the last week, it's fair to say advancements in the UK, EU, and US have rekindled our faith in medical progress. The UK set the pace with a revolutionary cancer drug approval. 🇬🇧 The game-changing therapy promises to target previously untreatable forms of the disease. This is not just hope; it's a tangible leap forward for patients entrenched in the fight of their lives. The NHS seems poised to fast-track this breakthrough, aiming to make it accessible, because, let's be honest, innovation without inclusion is no victory at all. Then we shift to the EU where a symphony of collaboration is reshaping Alzheimer's treatment. 🇪🇺 A pan-European consortium has pooled resources to decode one of humanity's most perplexing afflictions, unveiling a drug that could slow cognitive decline. The research hinges on an unprecedented dosage algorithm, personalising treatment like never before. We're seeing the EU's investment in unified health endeavors starting to see success. Across the pond, US biotech giants have joined forces in the war against antibiotic resistance. Leading pharmaceutical companies are sharing antibiotic data to outmaneuver resistant bacteria. This initiative marks a pivotal shift from competition to cooperation, realising that some fights are bigger than any single entity. Remember, behind every capsule, tablet, and injection is an epic tale of human ingenuity. Let's continue to support and advocate for industries and professionals who heal the world daily. 💊🌐✨ #HealthcareHeroes #PharmaInnovations #GlobalHealth

Was delighted to share my views on China's Life Sciences market with Pharma Boardroom lead editor and CEO Diana Viola just a few weeks ago. China's innovation capabilities have elevated so robustly, that global pharma co's now must include Chinese assets as true option to enhance their global portfolio.

Pharma companies invest millions in innovation each year. This graphic from Nicolas Schmitz clearly showcases the top pharmaceutical pipelines for 2024. However, the pressing question remains: how much of this innovation will extend beyond the US, EU and some selected Asian markets? Low- and middle-income countries around the world are unlikely to see many of these products become accessible. Why is this?  Over the years, I have focused on compassionate use and expanded access programs, helping small- to mid-sized companies strategize pathways to provide treatments to patients with life-threatening conditions. These regulatory frameworks allow patients to access drugs prior to formal approval when no other options are available. Even within these frameworks, disparities in access are significant—and the blame doesn’t solely rest with pharmaceutical companies strategies. A multitude of factors come into play. Together with Mimi Choon-Quinones Partners For Patients NGO WEP Clinical and other esteemed panelists, we will explore these disparities and discuss actionable steps to improve access to innovative medicines in underserved regions at the HEAL event in Davos next week. You can find more about this event here: https://lnkd.in/du-XMKUF Let's work towards a future where life-saving treatments are accessible to all, no matter where they live. #withEveryPatient #compassionateuse ---------------------------- Image Credits: Nicolas Schmitz

New China Pharma Report Exclusive Download China’s position as one of the top global sources and recipients of biopharmaceutical innovation is inarguable. As the Year of the Dragon draws to a close, leading Chinese life sciences stakeholders remain undimmed in their commitment to the country and the myriad opportunities to bring breakthroughs to patients, both within China’s borders and beyond. Healthcare & Life Sciences Review China 2024 draws from exclusive in-person conversations in hubs like Shanghai, Suzhou, and Beijing with biotech founders, country representatives of the world’s biggest multinationals, and thought leaders with vast experience in the China market. This exclusive new report covers the push towards prevention, chronic disease management, enhanced infrastructure, and homegrown innovation under the Healthy China 2030 initiative; China’s attempts to balance affordability with access to innovation; why Big Pharma is snapping up Chinese biotechs; and how multinationals are leveraging the country for R&D hubs, clinical trials, and tech-enabled drug discovery. Read more at: https://lnkd.in/dJkujPfJ Featuring the insights of: Guohong Shan Shui on Leung Fengmao Hua Yingjia Zhang Jens Ewert Vivian Zhang Chengbin Wu Vincent Chan Yu (Shawn) Xiang Renaud Gabay Yoshio UCHIDA Olivier Dessajan George Chen, MD, MBA Nisa Leung James Xue Jenny Lei ZHENG Xuefeng Yu Xueming Qian Guillaume Delmotte Yao-Chang Xu Jasmine Cui Jim Jin Allen Li Li Chen Ting Xu Cynthia Xin Wang

While I wish this announcement would’ve occurred during the peak of my time working with and advising biosimilar companies, it’s a welcomed shift nonetheless. As the industry continues to focus on cost-reduction strategies and patient outcomes, this news is particularly great for its potential to get patients accessible, impactful therapies quicker and cheaper. By eliminating redundant clinical trials, the FDA is paving the way for quicker adoption and greater availability of these life-saving treatments. This aligns with global standards set by the European Medicines Agency and ensures the USA stays competitive in drug development. AI-driven insights can further streamline the regulatory process, ensuring patients receive timely access to these cost-effective therapies without compromising safety. In this context, AI's role becomes crucial. By leveraging it with human expertise to analyze comparative analytical and clinical data, we can develop robust assessments that validate the safety and efficacy of switching between biosimilars and their reference products. Most importantly, as an industry, we can compound these savings to invest in further innovation and therapy advancements while passing lower costs to patients. https://lnkd.in/ejXcw2Dv.

Healthcare decisions should reflect patients' real experiences and needs, but to achieve this, we need to improve how we gather and apply Patient Engagement (PE) and Patient Experience Data (PED). A recent publication by Therapeutic Innovation & Regulatory Science (TIRS) shows: ✅ Interest in PE and PED is rapidly growing across regions, but more work is needed to combine them effectively in regulatory and health technology assessments (HTA). ✅ We must integrate PE at every stage of PED program design and interpretation to truly maximize patient input. ✅ A co-created framework is essential to bridge the gap between patient insights and decision-making in healthcare. We need your expertise to ensure that PE & PED Integrated Navigator addresses these gaps and works for all stakeholders. Your feedback here ➡️ https://lnkd.in/gk9rTDRx — Roche, Gilead Sciences, Novartis, Boehringer Ingelheim, UCB, BioCryst Pharmaceuticals, Inc., Pharma Deutschland, Chiesi Group

Welcome back to this series on how insights from the stock market are informing the future of healthcare! Today, we’re examining the significant role pharmaceutical companies play in public health through their investment strategies, with special insights from Dr. Chen about China's ascent in the global pharmaceutical industry.  Global Influence of Pharmaceuticals: Major pharmaceutical companies are key players in the public health ecosystem. Their investment decisions in research and development directly influence the availability and effectiveness of treatments worldwide. Dr. Chen discusses how Chinese pharmaceutical firms are extending their reach globally through strategic investments, with a strong focus on harnessing AI to streamline drug development. Dr Timmy from the UK adds that Drug Companies based in the West in Europe, UK and the Americas are on a similar mission. Dr Dwaye from Jamaca brings the discussion back to the focal point of any medical talk, the patient; saying 'they should all be working towards the improvement of patient care and well being and making these treatments affordable across the board'.  AI’s Impact on Drug Development: The integration of AI into pharmaceutical strategies is revolutionizing the industry by accelerating the timeline for bringing new drugs to market. These investments are particularly focused on innovative therapies for cancer, gene therapy, obesity, and antiviral medications, reflecting a proactive approach to tackling major health challenges.  Intersection of Stock Performance and Public Health: The performance of pharmaceutical stocks offers a reflection of their impact on public health outcomes. As these companies deploy resources towards groundbreaking treatments, their market valuation often intersects with their ability to enhance health care solutions.  Insights from Dr. Chen: "Chinese pharmaceutical companies are not just participating; they're increasingly leading the charge in the global market through innovations fuelled by AI," Dr. Chen points out. This leadership is crucial as it reshapes healthcare innovation and delivery across continents.  The Bigger Picture: As we proceed with our series, the strategic manoeuvres of big pharma under the microscope reveal how deeply financial investments are linked to the evolution of global healthcare. Join us tomorrow as we explore more about the direct impacts of these financial strategies on medical practices and the ethical considerations that accompany the commercialization of health. Feel free to share your perspectives on how pharmaceutical investments are reshaping healthcare in your community! #PharmaceuticalInvestments #AIinHealthcare #GlobalHealthDynamics #MedicalInnovation #StockMarketInsights #FutureOfHealthcare #TheBrandAEye

Our regular column where we select the latest published from September 2024 across the spectrum of #RWE and #HTA. This month, we feature: - Why is the market design for innovative pharmaceuticals not well understood? Francisco Olivença, Jose Diaz, Sreeram Ramagopalan and Lou Garrison Jr - Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment. David Campbell, Rajshree Pandey, Lisa Bloudek, Josh Carlson, Christopher Wallick, David Veenstra and Stacey Kowal - Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence. Jiyeon Kang and John Cairns - Development of a Canadian guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision making. @Mina Tadrous, Theresa Aves, Christine Fahim and colleagues - PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Kazuhiro Kajiyama, Maki Komamine, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama - Adopting a framework for rapid real-world data analyses in safety signal assessment. Lu Wang, Negar Golchin, Stephanie von Klot, Claudia A Salinas, Katrin Manlik, Vaishali Patadia, PhD, MBA, MPH, Mary K Miller, Julius Asubonteng, Rachel McDermott, Julie Barberio & Geoffrey Gipson - Examining the effect of missing data and unmeasured confounding on external comparator studies: case studies and simulations. Gerd Rippin, Héctor Sanz, Wilhelmina E Hoogendoorn, Nicolás M Ballarini, Joan A Largent, Eleni Demas, Douwe Postmus, Theodor Framke, Lukas M Aguirre Dávila, Chantal Quinten & Francesco Pignatti - Analytical methods for comparing uncontrolled trials with external controls from real-world data: a systematic literature review and comparison to European regulatory and health technology assessment practice. Milou A Hogervorst, Kanaka V Soman, Helga Gardarsdottir, Wim Goettsch & Lourens T Bloem - Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025. Emma M Cousin, Sean Sullivan, Ryan N Hansen, Nico Gabriel, Ayuri S Kirihennedige & Inmaculada (Inma) Hernandez Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

During the past few days, IFPMA delivered several statements representing the innovative pharmaceutical industry at the #WHA77. ◾With the Global Self-Care Federation, Global Medical Technology Alliance (#GMTA), Developing Countries Vaccine Manufacturers Network (DCVMN International), and the Biotechnology Innovation Organization, we stressed the life-sciences industry’s commitment to a pandemic agreement that strengthens the innovation ecosystem and encourages companies to develop the science and tools needed to respond to the next pandemic, while striving for more equitable access. ◾On the Working Group on Amendments to the International Health Regulations (2005) (#WGIHR), we appreciated the substantial collaborative efforts in advancing pandemic preparedness in the IHR text. However, we underscored that the draft still has open issues that may have a counterproductive impact, including unclear terminology. We urge Member States to ensure that technology transfer remains voluntary and on mutually agreed terms. ◾With IGBA - International Generic and Biosimilar medicines Association, Global Diagnostic Imaging, Healthcare IT, and Radiation Therapy Trade Association (#DITTA), Global Self-Care Federation, World Hypertension League, and PATH, we welcomed the WHO’s continued commitment to non-communicable diseases (NCDs). A life-course approach to tackling NCDs is critical given the unsustainable pressures the rising burden of chronic conditions and co-morbidities are placing on healthcare systems worldwide. ◾We have also delivered individual statements welcoming the strategic focus of the 14th General Programme of Work (#GPW14), supporting the WHA’s proposed strategic priorities on #AMR, and commending the resolution on climate change and health.   ➡View and download our positions: https://lnkd.in/eF-6nYCd

📢 Innovate Research is Proud to Announce a Significant Achievement We are excited to announce the successful completion of the Post-Marketing Surveillance clinical study for Asthma. As a leading Contract Research Organization (CRO), Innovate Research has once again demonstrated its exceptional expertise in clinical trials. 👨💼 A special thanks to Dr. Devesh Kumar, Dr. Piyush Kumar Pandey, Poonam Gupta, Rajat Singh Rathore, Pushkar raj Chandel, and Vaibhav Gupta for their unwavering dedication and hard work. We also extend our gratitude to our partners and participants for their invaluable contributions, which were essential in successfully managing 177 out of 178 patients. The utilization of in-house tools for efficient data handling and security #Clinsoft and #PageOne further streamlined the study process. 🫁 This achievement marks a major advancement in the Respiratory therapeutic area, and we take pride in our ongoing commitment to driving innovation in healthcare. Choose Innovate Research for unmatched expertise, streamlined execution, and meticulous project management across pharmaceutical, biotechnology, nutraceuticals and medical device studies. Let’s keep advancing the frontiers of healthcare innovation! 🌟 #ClinicalTrials #CROExcellence #InnovateResearch #HealthcareInnovation #Vaccines #medicalwriting #datamanagement #regulatoryservices #projectmanagement #successful #completion #clinicaloperations #sitemanagement #biostatistics #biospecimen #studyfeasibility #research #cro #biospecimen #pharmaceuticals #drugsafety #drugdevelopment #clinicaltrials #Asthma #RespiratoryDiseases